Drug Mechanism Enrichment Analysis: A tool to link molecular signatures with sensitivity to drug mechanisms of action
暂无分享,去创建一个
[1] U. Sauer,et al. High‐throughput metabolomics predicts drug–target relationships for eukaryotic proteins , 2022, Molecular systems biology.
[2] A. Haslam,et al. Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.
[3] Wenyu Lin,et al. SLC7A11/xCT in cancer: biological functions and therapeutic implications. , 2020, American journal of cancer research.
[4] L. Zhuang,et al. Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy , 2020, Protein & Cell.
[5] Sanghyun Park,et al. RefDNN: a reference drug based neural network for more accurate prediction of anticancer drug resistance , 2020, Scientific Reports.
[6] Joshua A. Bittker,et al. Discovering the anticancer potential of non-oncology drugs by systematic viability profiling , 2020, Nature Cancer.
[7] Andrew R. Leach,et al. Drug mechanism‐of‐action discovery through the integration of pharmacological and CRISPR screens , 2020, bioRxiv.
[8] M. Sciandrone,et al. Modeling cancer drug response through drug-specific informative genes , 2019, Scientific Reports.
[9] A. Lin,et al. Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials , 2019, Science Translational Medicine.
[10] G. Lippi,et al. Statins popularity: A global picture , 2019, British journal of clinical pharmacology.
[11] D. Pang,et al. Ferritinophagy is required for the induction of ferroptosis by the bromodomain protein BRD4 inhibitor (+)-JQ1 in cancer cells , 2019, Cell Death & Disease.
[12] Xiaoqi Zheng,et al. Comprehensive anticancer drug response prediction based on a simple cell line-drug complex network model , 2019, BMC Bioinformatics.
[13] R. Eckert,et al. Chk1 inhibition as a novel therapeutic strategy in melanoma , 2018, Oncotarget.
[14] T. Graeber,et al. Multi-stage Differentiation Defines Melanoma Subtypes with Differential Vulnerability to Drug-Induced Iron-Dependent Oxidative Stress. , 2018, Cancer cell.
[15] Gary Middleton,et al. Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer. , 2018, Cancer discovery.
[16] Denis Bertrand,et al. Predicting Cancer Drug Response Using a Recommender System , 2017, bioRxiv.
[17] Jill P. Mesirov,et al. Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway , 2017, Nature.
[18] Angela N. Brooks,et al. A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles , 2017, Cell.
[19] Pedro J Ballester,et al. Systematic assessment of multi-gene predictors of pan-cancer cell line sensitivity to drugs exploiting gene expression data , 2016, bioRxiv.
[20] Hristo S. Paskov,et al. Multitask learning improves prediction of cancer drug sensitivity , 2016, Scientific Reports.
[21] Emanuel J. V. Gonçalves,et al. A Landscape of Pharmacogenomic Interactions in Cancer , 2016, Cell.
[22] K. Akashi,et al. The EGF Receptor Promotes the Malignant Potential of Glioma by Regulating Amino Acid Transport System xc(-). , 2016, Cancer research.
[23] Joshua A. Bittker,et al. Correlating chemical sensitivity and basal gene expression reveals mechanism of action , 2015, Nature chemical biology.
[24] Joshua A. Bittker,et al. Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset. , 2015, Cancer discovery.
[25] Matthew E. Ritchie,et al. limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.
[26] J. Utikal,et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. , 2014, The New England journal of medicine.
[27] G. Drewes,et al. Tracking cancer drugs in living cells by thermal profiling of the proteome , 2014, Science.
[28] K. Yoon,et al. Effect of simvastatin on the resistance to EGFR tyrosine kinase inhibitors in a non-small cell lung cancer with the T790M mutation of EGFR. , 2014, Experimental cell research.
[29] J. Hou,et al. Atorvastatin overcomes gefitinib resistance in KRAS mutant human non-small cell lung carcinoma cells , 2013, Cell Death and Disease.
[30] Joshua C. Gilbert,et al. An Interactive Resource to Identify Cancer Genetic and Lineage Dependencies Targeted by Small Molecules , 2013, Cell.
[31] S. Ramaswamy,et al. Systematic identification of genomic markers of drug sensitivity in cancer cells , 2012, Nature.
[32] Adam A. Margolin,et al. The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.
[33] Yu Shyr,et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. , 2012, The New England journal of medicine.
[34] J. Boerner,et al. Lipid raft localization of EGFR alters the response of cancer cells to the EGFR tyrosine kinase inhibitor gefitinib , 2011, Journal of cellular physiology.
[35] Wei Zhou,et al. In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models , 2009, Clinical Cancer Research.
[36] Anil Potti,et al. Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors , 2006, BMC Genomics.
[37] R. Shoemaker. The NCI60 human tumour cell line anticancer drug screen , 2006, Nature Reviews Cancer.
[38] Chan Zeng,et al. Baseline Gene Expression Predicts Sensitivity to Gefitinib in Non–Small Cell Lung Cancer Cell Lines , 2006, Molecular Cancer Research.
[39] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[40] C. Stancu,et al. Statins: mechanism of action and effects , 2001, Journal of cellular and molecular medicine.
[41] J. Mesirov,et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. , 1999, Science.
[42] Jacob D. Jaffe,et al. Next-generation characterization of the Cancer Cell Line Encyclopedia , 2019, Nature.